DigestRedComo funciona
Red
/
Empresas
Mi
No verificado

Minerva Neurosciences, Inc

Sobre qué escribimos

FinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

7 Comunicados de prensa

Ver todos los comunicados de prensa
19/11/2025
Medicina Salud Bienestar
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
05/11/2025
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
21/10/2025
Medicina Salud Bienestar
Finanzas
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
14/08/2025
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
13/05/2025
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
25/02/2025
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0
05/11/2024
Medicina Salud Bienestar
Gestión empresarial/Administración de Empresas
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Fuente
Minerva Neurosciences, Inc
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0